XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$28.19 USD
-1.66 (-5.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $28.49 +0.30 (1.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XOMA 28.19 -1.66(-5.56%)
Will XOMA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XOMA
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?
Other News for XOMA
XOMA Royalty to Present at Upcoming Investor Conferences in September
Risinger Affirms Buy Rating on Xoma with Increased Price Target Amid Strong Financial Performance and Unrecognized Asset Potential
Buy Rating Affirmed: Xoma’s Strategic Growth and Financial Strength Highlighted
Xoma price target raised by $43 at H.C. Wainwright, here's why
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024